XML 15 R3.htm IDEA: XBRL DOCUMENT v3.22.2.2
Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)
$ / shares in Thousands, $ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Unrestricted cash and cash equivalents $ 352,908 $ 409,660
Restricted cash and cash equivalents 33,783 96,968
Loans, interest and fees receivable, at fair value 1,728,091 1,026,424
Loans, interest and fees receivable, gross 107,410 470,293
Allowances for uncollectible loans, interest and fees receivable 1,766 57,201
Deferred revenue 16,560 29,281
Notes payable, at face value $ 1,544,108 $ 1,278,864
Common stock, par value (in dollars per share) $ 0 $ 0
Common stock, authorized (in shares) 150,000,000 150,000,000
Common stock, issued (in shares) 14,445,295 14,804,408
Common stock, outstanding (in shares) 14,445,295 14,804,408
Series A Preferred Stock [Member]    
Preferred stock, shares authorized (in shares) 10,000,000 10,000,000
Preferred stock, shares issued (in shares) 400,000 400,000
Preferred stock, shares outstanding (in shares) 400,000 400,000
Preferred stock, liquidation preference $ 40,000 $ 40,000
Series B Preferred Stock [Member]    
Preferred stock, no par value (in dollars per share) $ 0 $ 0
Preferred stock, shares issued (in shares) 3,193,262 3,188,533
Preferred stock, shares outstanding (in shares) 3,193,262 3,188,533
Preferred stock, liquidation preference $ 79,800 $ 79,800
Variable Interest Entity, Primary Beneficiary [Member]    
Unrestricted cash and cash equivalents 186,600 209,500
Restricted cash and cash equivalents 15,800 75,900
Loans, interest and fees receivable, at fair value 1,618,200 925,500
Loans, interest and fees receivable, gross 0 369,600
Allowances for uncollectible loans, interest and fees receivable (0) 55,100
Deferred revenue (0) 8,200
Notes payable, at face value $ 1,473,000 $ 1,223,400